AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board

Utrecht, The Netherlands, 1 July 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board. With over 20 years of experience in pharmaceutical development, Dr. Jain most recently was Senior Vice President and Chief Medical Officer at […]

AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team

Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development. Dr. Meder, who brings nearly 20 years of […]

AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury

Juliane Bernholz has joined as Chief Operating Officer Kristie Bass has joined as VP Clinical Operations Bunnik, The Netherlands, 1 October 2019 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP) today […]

AM‐Pharma Announces Appointment of Industry Expert Guido Magni as Board Member

Bunnik, The Netherlands, 16 March 2012. AM‐Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and inflammatory bowel diseases, has appointed Dr Guido Magni as a member of its Supervisory Board. Dr Magni MD PhD was trained as an MD […]

AM-Pharma Announces Appointment of Russell Greig as Chairman

Bunnik, The Netherlands, 4 January 2012. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board. Dr Greig served nearly three decades with […]

AM-Pharma appoints Erik van den Berg as CEO

Bunnik, The Netherlands, 2 September 2011. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for the treatment of severe inflammatory diseases, today announced the appointment of Erik van den Berg, previously VP Business Development of AM-Pharma as CEO of the company. Bart Wuurman, who has led the […]

AM-Pharma announces appointment of new VP Clinical Development

Bunnik, The Netherlands, 18 February 2008. AM-Pharma B.V., the biopharmaceutical company developing optimised endogenous proteins and peptides to combat disease, today announced the appointment of Jacques Arend as Jacques Arend, MD joined the pharmaceutical industry in 1988, in medical and clinical development positions. He started at SmithKline Beecham, and then became international coordinator clinical development […]

AM-Pharma announces appointment of Chief Business Officer

Bunnik, The Netherlands, 17 September 2007. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the appointment of Erik van den Berg as Chief Business Officer. Erik van den Berg MSc MBA, joins from Organon, where he was leading the global biotech business development efforts. Prior to joining Organon, he […]

AM-Pharma announces the appointment of Bart Wuurman as CEO

Bart Wuurman, M. Sc. replaces Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December 2006. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry experience with Organon, Medeva and Antisoma, where he was responsible for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, […]